Single Chain Antibody Vaccination in Mice Against Human Ovarian Cancer Enhanced by Microspheres and Cytokines

References

• Ayala, M., Duenas, M., Santos, A., Vazquez, J., Menendez, A., Silva, A. and Gavilondo, J.V. (1992) “Bacterial single-chain antibody fragments, specific for carcinoembryonic antigen”, Biotechniques 13, 790–799.
   PubMed Web of Science ®Google Scholar
• Cochet, O., Gruel, N., Fridman, W.H. and Teillaud, J.L. (1999) “Ras and p53 intracellular targeting with recombinant single chain Fv (scFv) fragments: a novel approach for cancer therapy?”, Cancer Detect. Prev. 23, 506–510.
   PubMedGoogle Scholar
• Costello, R.T. (1993) “Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience”, Acta Oncol. 32, 403–408.
   PubMed Web of Science ®Google Scholar
• Courtenay-Luck, N.S., Epenetos, A.A., Sivolapenko, G.B., Larche, M., Barkans, J.R. and Ritter, M.A. (1988) “Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies”, Lancet 2, 894–897.
   PubMed Web of Science ®Google Scholar
• De Wit, D., Van Mechelen, M., Ryelandt, M., Figueiredo, A.C., Abramowicz, D., Goldman, M., Bazin, H., Urbain, J. and Leo, O. (1992) “The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes”, J. Exp. Med. 175, 9–14.
   PubMed Web of Science ®Google Scholar
• Durrant, L.G., Maxwell-Armstrong, C., Buckley, D., Amin, S., Robins, R.A., Carmichael, J. and Scholefield, J.H. (2000) “A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55”, Clin. Cancer Res. 6, 422–430.
   PubMed Web of Science ®Google Scholar
• Eldridge, J.H., Staas, J.K., Meulbroek, J.A., Tice, T.R. and Gilley, R.M. (1991) “Biodegradable and biocompatible poly(DL-lactide-co-glyco- lide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies”, Infect. Immun. 59, 2978–2986.
   PubMed Web of Science ®Google Scholar
• Fagerberg, J., Frodin, J.E., Ragnhammar, P., Steinitz, M., Wigzell, H. and Mellstedt, H. (1994) “Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1) II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?”, Cancer Immunol. Immunother. 38, 149–159.
   PubMed Web of Science ®Google Scholar
• Foon, K.A., Bhattacharya-Chatterjee, M., et al. (2001) “Are solide tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner.Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment”, Clin. Cancer Res. 7, 1154–1162.
   PubMed Web of Science ®Google Scholar
• Golumbek, P.T., Azhari, B., Jaffee, E.M., Levitsky, H.I., Lazenby, A., Leong, K. and Pardoll, D.M. (1993) “Controlled release, biodegrad- able cytokine depots: a new approach in cancer vaccine design”, Cancer Res. 53, 5841–5844.
   PubMed Web of Science ®Google Scholar
• Guo, Y.J., Che, X.Y., Shen, F., Xie, T.P., Ma, J., Wang, X.N., Wu, S.G., Anthony, D.D. and Wu, M. (1997) “Effective tumor vaccines generated by in vitro modification of tumor cells with cytokines and bispecific monoclonal antibodies”, Nat. Med. 3, 451–455.
   PubMed Web of Science ®Google Scholar
• Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S. and Gupta, C.K. (1993) “Adjuvants—a balance between toxicity and adjuvanticity”, Vaccine 11, 293–306.
   PubMed Web of Science ®Google Scholar
• Hasholzner, U., Stieber, P., Meier, W. and Lamerz, R. (1997) “Value of HAMA-determination in clinical practice—an overview”, Anticancer Res. 17(4B), 3055–3058.
   Google Scholar
• Hawkins, R.E., Zhu, D., Ovecka, M., Winter, G., Hamblin, T.J., Long, A. and Stevenson, F.K. (1994) “Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines”, Blood 83, 3279–3288.
   PubMed Web of Science ®Google Scholar
• Herlyn, D., Herlyn, M., Steplewski, A. and Koprowski, H. (1985) “Monoclonal anti-human tumor antibodies of six isotypes in cytotoxic reactions with human and murine effector cells”, Cell Immunol. 92, 105–114.
   PubMed Web of Science ®Google Scholar
• Huang, J.H., Ward, R.E. and Kohler, H. (1986) “Idiotope antigens (Ab2a and Ab2b) can induce in vitro B cell proliferation and antibody production”, J. Immunol. 137, 770–776.
   PubMed Web of Science ®Google Scholar
• International Collaborative Ovarian Neoplasm Group (2002) “Paclitaxel plus carboplatin versus standard chemotherapy with either single- agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial”, Lancet 360, 505–515.
   PubMed Web of Science ®Google Scholar
• Jean, D. and Bar-Eli, M. (2001) “Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: potential modality for cancer therapy”, Crit. Rev. Immunol. 21, 275–286.
   PubMed Web of Science ®Google Scholar
• Jerne, N.K., Roland, J. and Cazenave, P.A. (1982) “Recurrent idiotopes and internal images”, EMBO J. 1, 243–247.
   PubMed Web of Science ®Google Scholar
• Kohler, H., Kaveri, S., Kieber-Emmons, T., Morrow, W.J., Muller, S. and Raychaudhuri, S. (1989) “Idiotypic networks and nature of molecular mimicry: an overview”, Methods Enzymol. 178, 3–35.
   PubMed Web of Science ®Google Scholar
• Kosmas, C., Epenetos, A.A. and Courtenay-Luck, N.S. (1994) “Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer”, Cancer 73, 3000–3010.
   PubMed Web of Science ®Google Scholar
• Luo, D., Geng, M., Noujaim, A.A. and Madiyalakan, R. (1997) “An engineered bivalent single-chain antibody fragment that increases antigen binding activity”, J. Biochem. (Tokyo) 121, 831–834.
   PubMed Web of Science ®Google Scholar
• Ma, J., Samuel, J., Kwon, G.S., Noujaim, A.A. and Madiyalakan, R. (1998) “Induction of anti-idiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable micro- spheres”, Cancer Immunol. Immunother. 47, 13–20.
   PubMed Web of Science ®Google Scholar
• Ma, J., Luo, D., Qi, W. and Cao, L. (2001) “Antitumor effect of the idiotypic cascade induced by an antibody encapsulated in poly(D,L-lactide-co-glycolide) microspheres”, Jpn J. Cancer Res. 92, 1110–1115.
   PubMedGoogle Scholar
• Men, Y., Thomasin, C., Merkle, H.P., Gander, B. and Corradin, G. (1995) “A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide”, Vaccine 13, 683–689.
   PubMed Web of Science ®Google Scholar
• Mittelman, A., Chen, Z.J., Kageshita, T., Yang, H., Yamada, M., Baskind, P., Goldgerg, N., Puccio, C., Ahmed, T., Arlin, Z. and Ferrone, S. (1990) “Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies”, J. Clin. Investig. 86, 2136–2144.
   PubMed Web of Science ®Google Scholar
• Mittelman, A., Chen, G.Z., Wong, G.Y., Liu, C., Hirai, S. and Ferrone, S. (1995) “Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma”, Clin. Cancer Res. 1, 705–713.
   PubMed Web of Science ®Google Scholar
• Nicholson, S., Gooden, C.S., Hird, V., Maraveyas, A., Mason, P., Lambert, H.E., Meares, C.F. and Epenetos, A.A. (1998) “Radio- immunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis”, Oncol. Rep. 5, 223–226.
   PubMed Web of Science ®Google Scholar
• Old, L.J. (1996) “Immunotherapy for cancer”, Sci. Am. 275, 136–143.
   PubMed Web of Science ®Google Scholar
• Poljak, R.J. (1994) “An idiotope-anti-idiotope complex and the structural basis of molecular mimicking”, Proc. Natl Acad. Sci. USA 91, 1599–1600.
   PubMed Web of Science ®Google Scholar
• Saeki, Y., Chen, J.J., Shi, L.F., Okuda, Y. and Kohler, H. (1990) “Idiotype-specific T helper clones recognize a variable H chain determinant”, J. Immunol. 144, 1625–1628.
   PubMed Web of Science ®Google Scholar
• Schick, M.R., Dreesman, G.R. and Kennedy, R.C. (1987) “Induction of an anti-hepatitis B surface antigen response in mice by noninternal image (Ab2) anti-idiotypic antibodies”, J. Immunol. 138, 3419–3425.
   PubMed Web of Science ®Google Scholar
• Schultes, B.C., Reinsberg, J., Schlebusch, H., Oehr, P., Biersack, H.J., Krebs, D. and Wagner, U. (1993) “Idiotypic cascades after injection of the monoclonal antibody OC125: a study in a mouse model. Induction of antibodies against OC125 and CA125 after immuniz- ation with an anti-CA 125 (MAb OC125) monoclonal antibody by activation of the idiotypic network”, Eur. J. Clin. Chem. Clin. Biochem. 31, 427–432.
   PubMedGoogle Scholar
• Sedlik, C., Perraut, R., Bonnemains, B. and Leclerc, C. (1996) “Antigens linked to synthetic microspheres induce immune responses in primates in the absence of adjuvant”, Immunobiology 195, 105–118.
   PubMed Web of Science ®Google Scholar
• Thielemans, K., Maloney, D.G., Meeker, T., Fujimoto, J., Doss, C., Warnke, R.A., Bindl, J., Gralow, J., Miller, R.A. and Levy, R. (1984) “Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas”, J. Immunol. 133, 495–501.
   PubMed Web of Science ®Google Scholar
• Uchida, T., Goto, S. and Foster, T.P. (1995) “Particle size studies for subcutaneous delivery of poly(lactide-co-glycolide) microspheres containing ovalbumin as vaccine formulation”, J. Pharm. Pharmacol. 47, 556–560.
   PubMed Web of Science ®Google Scholar